期刊文献+

Ⅲ期结直肠癌术后经肝动脉灌注联合静脉辅助化疗的临床观察 被引量:3

Clinical observation of postoperative hepatic arterial infusion and systemic adjuvant chemotherapy in patients with stage Ⅲcolorectal cancer
暂未订购
导出
摘要 目的:通过与静脉辅助化疗对照,观察经肝动脉灌注联合静脉辅助化疗对Ⅲ期结直肠癌术后肝转移、无病生存期及总生存期的影响。方法:2002年1月至2006年3月,21例Ⅲ期结直肠癌患者作为治疗组,术后给予肝动脉灌注FUDR联合静脉应用草酸铂化疗,同期对照21例Ⅲ期结直肠癌患者,术后给予草酸铂联合CF/5-FU静脉化疗。主要观察终点为肝转移率及DFS,次要终点为OS和用药安全性。结果:中位随访65(9~119)个月,治疗组肝转移发生率较低(9.5%vs.28.6%,P=0.109),肺转移发生率略高(28.6%vs.14.3%,P=0.256)。2组5年DFS(38.1%vs.42.9%,P=0.671)及OS(47.9%vs.45.0%,P=0.784)无统计学差异。化疗副反应多为Ⅰ~Ⅱ度血白细胞减少、恶心呕吐及感觉神经障碍。结论:Ⅲ期结直肠癌术后给予经肝动脉联合静脉系统化疗,与静脉化疗相比,可能会降低肝转移的发生率,DFS及OS无统计学差异,化疗副反应较轻,可耐受。 Objective: This study aims to investigate whether postoperative hepatic arterial infusion combined with systemic adjuvant chemotherapy is more effective compared with systemic adjuvant chemotherapy alone in terms of survival and liver metastasis for patients with stage Ⅲ colorectal cancer. Methods: From January 2002 to March 2006, 21 patients with stage Ⅲ colorectal cancer were assigned to postoperative locoregional chemotherapy with fluorodeoxyuridine and systemic adjuvant chemotherapy with oxaliplatin (treatment group). Another group of 21 patients were assigned to the systemic adjuvant chemotherapy with oxaliplatin as well as fluorouracil and folinic acid (control goup). The primary endpoint of the observation included 5-year disease-free survival (DFS) and liver metastasis. The secondary endpoint was the overall survival (OS) and toxic effects. Results: Median follow-up was 65 months (range: 9 months to 119 months). The incidence rate of liver metastasis in patients who underwent hepatic arterial infusion and systemic chemotherapy was 9.5%, whereas that in patients who underwent systemic chemotherapy alone was calculated at 28.6% (P=-0.109). By contrast, the incidence of lung metastasis was relatively higher; however, the difference was not significant (28.6% vs. 14.3%, P =0.256). No significant difference in the 5-year DFS (38.1% vs. 42.9%, P=0.671) and the 5-year OS (47.9%vs. 45.0%,P-0.784) was indicated between the two groups. Toxicities such as reduction in leukocytes as well as nausea and peripheral neurosensory toxicity were mild and could be treated by medication. Conclusion: Postoperative hepatic arterial infusion combined with systemic chemotherapy can possibly reduce the occurrence of liver metastasis, but may add no further benefit to the DFS and OS of the patients with stageⅢ cancer obtaining systemic chemotherapy alone. The toxicities were mild and tolerable.
出处 《中国肿瘤临床》 CAS CSCD 北大核心 2013年第1期32-35,共4页 Chinese Journal of Clinical Oncology
关键词 结直肠癌 肝动脉灌注 辅助化疗 colorectal cancer hepatic arterial infusion chemotherapy
  • 相关文献

参考文献10

  • 1Taylor L. Adjuvant chemotherapy after resection of fiver metasta- ses from colorectal cancer[J]. EurJ Cancer, 2008, 44(9):1198-1201.
  • 2Nordlinger B, Rougier P, Arnand JP, et al. Adjuvant regional che- motherapy and systemic chemotherapy versus systemic chemother- apy alone in patients with stage colorectal cancer: a multicen- tre randomised controlled phase trial[J]. Lancet Oncol. 2005 ,6 (7) :459-468.
  • 3BoltonJS, O'Connell MJ, Mahoney MR, et al. Hepatic arterial infusion and systemic chemotherapy after multiple metastasectomy in patients with colorectal carcinoma metastatic to the liver: a North Central Cancer Treatment Group (NCCTG) phase ]] study, 92-46-52[J].Clin Colorectal Cancer, 2012, 11 (1):31-37.
  • 4Xu J, Zhong Y, Weixin N, et al. Preoperative hepatic and regional arterial chemotherapy in the prevention of liver metastasis after colorectal cancer surgery[J]. Ann Surg, 2007, 245(4):583-590.
  • 5Sadahiro S, Suzuki T, Ishikawa K, et al. Prophylactic hepatic arteri- al infusion chemotherapy for the prevention of liver metastasis in patients with colon carcinoma: a randomized control trial[J]. Can- cer, 2004, 100(3):590-597.
  • 6Jonker DJ, Spithoff K, Maroun J, et al. Adjuvant systemic chemo- therapy for Stage lI and 11I colon cancer after complete resection: an updated practice guideline[J]. Clin Oncol, 2011, 23(5) :314-322.
  • 7马力文,肖宇,张照辉,曹宝山,杨静,王墨培,张淑兰,梁莉,李选.氟脲苷肝动脉持续灌注联合草酸铂静脉化疗治疗肝转移癌[J].中国肿瘤临床与康复,2005,12(6):513-516. 被引量:4
  • 8Samaras P, Breitenstein S, Halle SR, et al. Selective intra-arterial chemotherapy with floxuridine as second- or third-line approach in patients with unresectable colorectal liver metastases[J]. Ann Surg Oncol, 2011, 18(7):1924-1931.
  • 9Bouchahda M, L6vi F, Adam R, et al. Modem insights into hepatic arterial infusion for liver metastases from colorectal cancer[J]. EurJ Cancer, 2011, 47(18):2681-2690.
  • 10王墨培,马力文,张淑兰,王俊杰,贾廷珍.含草酸铂化疗方案治疗大肠癌神经毒性的临床研究[J].肿瘤防治杂志,2004,11(2):168-170. 被引量:20

二级参考文献21

  • 1庄一平,陈世唏,徐向红,张晓,张晋.胃、结直肠癌肝转移的介入治疗(附55例报告)[J].实用医学影像杂志,2001,2(3):159-161. 被引量:3
  • 2Raymond E,Chaney S G,Taama A,et al. Oxaliplatin:A review of preclinical and clinical studies[J].Ann Oncol,1998,9(10):1053-1071.
  • 3Levi F,Misset J L,Brienza. Achronopharmacologic phaseⅡclinical tial with 5-fluorouracil,folinicacid,and oxaliplatin using an ambulatorymultichannel programmable pump:high antitumor effectiveness against metastasis colorectal cancer[J].Cancer,1992,69(4):893-900.
  • 4Levi F,Perpoint B. A multicenter phaseⅡtrial of intensified chronotherapy with oxaliplatin,5-fluorouracil and folinic acid in padents with previous untreated metastatic colorectal cancer(Abstr)[J].Proc Am soc clin oncol,1997,16(5):266.
  • 5Richard H,Wilson,Tanya lehky,Rebecca R.Thonas.Acute Oxaliplatin-induced peripheral Nerve Hyperexcitability[J].Journal of clinical oncology,2002,20(16):3561-3562.
  • 6Misset J L,Brienza S,Taamma A. Pharmacokinetics,urinary and fecal excretion of oxaliplatin in cancer patients[J].Am Ass Cancer Res Meeting abstract,1996,5(37):1252-1255.
  • 7Grolleau F,Gamelin L,Boisdron-celle M,et al. A possible Explanation for a Neurotoxic Effect of the Anticancer agent oxaliplatin on Neuronal Volgage-Gated Sodium channels[J].The American Physiological Society,2001,85(5):2293-2297.
  • 8Mckeage M J,Hsu T,Screnci D. Nucleolar damage correlates with neurotoxicity induced by different platinum drugs[J].British journal of Cancer,2001,85(8):1219-1225.
  • 9Cascinu S,Catalano V,Cordella L,et al. Neuroprotective effect of reduced glutathione on oxaliplatin-based chemothera in advanced colorectal cancer:a randomized,double-blind,placebo-controlled trial[J].Clin Oncol,2002,20(16):3478-3483.
  • 10Allain P,Heudi O,Cailleux A. Early biotransformations of oxaliplatin after its intravenous administration to cancer patients[J]. Drug Metab Dispos,2000,28(11):1379-1384.

共引文献22

同被引文献34

  • 1王培培,王军,齐曼,郭银,李娜,武亚晶,焦文鹏,王丽,张彦军.直肠癌术后三维适形/调强放疗联合化疗与单纯辅助化疗的疗效比较[J].肿瘤防治研究,2014,41(5):468-473. 被引量:18
  • 2Chan DL, Alzahrani NA, Morris DL, et al. Systematic review and meta-analysis of hepatic arterial infusion chemotherapy as bridging therapy for colorectal liver metastases. Surg Oncol, 2015,24 ( 3 ) : 162 - 171.
  • 3Shi L, Zhao J, Lu Q, et al. Initial hepatic artery infusion and systemic chemotherapy for asymptomatic colorectal cancer with un-resectable liver metastasis. Int J Clin Exp Med,2015,8( 1 ) :1000 - 1008.
  • 4Alberts SR, Roh MS, Maboney MR, et al. Alternating systemic and hepatic artery infusion therapy for resected liver metastases from colorectal cancer: a North Central Cancer Treatment Group (NCCTG)/National Surgical Adjuvant Breast and Bowel Project (NSABP) phase lI intergroup trial, N9945/CI-66. J Clin Oncol, 2010,28(5) :853 -858.
  • 5Prigerson HG, Bao Y, Shah MA, et al. Chemotherapy use, performance status, and quality of llfe at the end of life. JAMA Oncol,2015,1 (6) :778 -784.
  • 6孙燕,主编.内科肿瘤学.第1版.北京:人民卫生出版社,2007.995-996.
  • 7Allard MA, Malka D. Place of hepatic intra-arterial chemotherapy in the treatment of eoloreetal liver metastases. J Vise Surg,2014,151 (1):21 -24.
  • 8Moeellin S, Pasquali S, Nitti D. Fluoropyrimidine-HAI ( hepaticarterial infusion) versus systemic chemotherapy ( SCT ) for unreseetable liver metastases from eolorectal cancer. Cochrane Database Syst Rev,2009,8 (3) : CD007823.
  • 9Boige V, Malka D, Elias D, et aL Hepatic arterial infusion of oxaliplatin And intravenous LV5FU2 in unresectable liver metastases from colorectal cancer after systemic chemotherapy failure. Ann Surg Oneol, 2008,15 ( 1 ) :219 - 226.
  • 10Cassidy J, Clarke S, Diaz-Rubio E,et al. Randomized phase Ⅲ study of capecitabine plus oxaliplatin compared with fluorouracil/folinie acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin 0ncol,2008,26(12) :2006 - 2012.

引证文献3

二级引证文献29

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部